



Susan Knox

Associate Professor of Radiation Oncology, Emerita
Radiation Oncology - Radiation Therapy

CONTACT INFORMATION

- **Administrative Contact**

Tanaya Kollipara - Assistant Clinical Research Coordinator

Email tanayak1@stanford.edu

Tel 650-723-5055

Bio

BIO

Dr. Susan Knox specializes in the treatment of breast cancer and melanoma, and sees a variety of general radiation oncology patients. She has practiced as a radiation oncologist for more than 25 years.

A primary area of research in Dr. Knox's laboratory is the study of novel therapies (targeted therapies, radiosensitizers, radioprotectors, and biological response modifiers) for the treatment of solid tumors, with a particular focus on prostate cancer, breast cancer and melanoma, using small animal tumor models. Her research is interdisciplinary and spans the study of mechanisms of action at the molecular level to translational studies and early clinical trials. Her drug discovery/development work, and research on innovative therapeutic approaches has resulted in 3 new ongoing clinical trials. A major focus of both her laboratory and clinical research is the use of radiation as a component of in situ tumor vaccine strategies. She has had a long - standing interest in clinical research and has served as a PI on numerous clinical trials and as a member of the Clinical Oncology Study Section. As the Faculty Director of the PRMS for the Stanford Cancer Institute, she oversees the Scientific Review Committee and chairs the Data and Safety Monitoring Committee.

ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Radiation Oncology - Radiation Therapy
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Associate Dean for Academic Advising, Stanford University School of Medicine, (2020- present)
- Program Evaluation Committee Member, Department of Radiation Oncology, (2014- present)
- Working Group Member, Society of Nuclear Medicine and Molecular Imaging, (2014- present)
- Committee Member, Stanford University on Health and Safety, (2013-2016)
- Executive Committee Member: Cancer Clinical Trials Office, Stanford Cancer Center, (2011- present)
- Executive Committee Member: Clinical Research Oversight Group, Stanford Cancer Center, (2011- present)

- Department Representative, School of Medicine Faculty Senate, (2011-2016)
- Committee Member, SAMFUND Selection Committee, (2010- present)
- Committee Member, SPARK Committee, (2009- present)
- BioX Program Member, Stanford University, (2008- present)
- Lymphoma Disease Management Group Member, Stanford Cancer Center, (2008- present)
- The Molecular Therapeutics Program, Stanford Cancer Center, (2008- present)
- Committee Member, Committee on Professionalism, Performance and Promotion, (2007- present)
- Committee on the State of Science in Nuclear Medicine, Subcommittee on Targeted Radiotherapy, The National Academies, (2006- present)
- Advisory Board and Training Committee, NIH T32 SCIT CA09695, (2005- present)
- Medical Education Leadership Group, Stanford Cancer Center, (2005- present)
- President, Alumni Association, Stanford School of Medicine, (2005-2007)
- Director, Core: Protocol Review and Monitoring System, Stanford Cancer Center, (2004- present)
- Chair, Data and Safety Monitoring Committee, Stanford Clinical Trials Office, Cancer Center, (2003- present)
- Executive Committee, Clinical Cancer Center, (2003- present)
- Associate Editor, Journal of Clinical Oncology, (2003-2006)
- Assistant Dean for Medical Student Advising, Stanford University School of Medicine, (2002- present)
- Member, Clinical Oncology Study Section, (2001-2004)
- Board of Governors, Stanford Medical Alumni Association, (2000-2007)
- Associate Editor, Radiation Research, (2000-2003)
- Editorial Board Member, Cancer Biotherapy and Radiopharmaceuticals, (1996- present)

HONORS AND AWARDS

- President, Alumni Association, Stanford University School of Medicine (2005-2007)
- Elected Councilor Medicine, Radiation Research Society (2003)
- Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation (2000-2002)
- Board of Governors, Stanford Medical Alumni Association (2000-2008)
- Lazard Faculty Scholar, Lazard Faculty (1992-93)
- Clinical Oncology Career Development Award, American Cancer Society (1991-94)
- Leadership in Education, Stanford University School of Medicine (2008)

PROFESSIONAL EDUCATION

- Post Doc Fellow, Stanford Univ. Hospital , Medical Oncology (1989)
- Medical Intern, UC Davis, California (1986)
- Post-Doc Fellow/Res. Assist., Stanford Univ. Hospital , Medical Oncology (1989)
- MD, Stanford University (1985)
- Post-Doc Res. Immunologist, UC Davis, California , Energy-Related Health Research
- PhD, UC Davis, California (1980)
- AB, UC Berkeley, California, (1974)

LINKS

- <https://web.stanford.edu/group/RIT>: <https://web.stanford.edu/group/RIT>

- Personal Web site / Radiation Oncology (Dept) Web site: <https://web.stanford.edu/group/RIT>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

- Radioimmunotherapy (RIT) and Systemically Targeted Radiation Therapy
- Low Dose Rate Effects
- Radioprotective Agents, Growth Factors/Receptors
- Oncogenes, Apoptosis & Radiosensitivity
- Apoptosis and Signal Transduction Pathways
- Effects of Radiation on the Immune Response
- Biological Response Modifiers and Novel Targeted Radiosensitizers
- Non-Hodgkin's Lymphomas
- Mycosis Fungoides
- Breast and Prostate Cancer
- Radiation as a component of Tumor Vaccine Strategies

CLINICAL TRIALS

- Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy, Not Recruiting
- Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma, Not Recruiting
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCL, Not Recruiting
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy, Not Recruiting
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma, Not Recruiting
- Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer, Not Recruiting
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy, Not Recruiting
- Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone, Not Specified

Teaching

STANFORD ADVISEES

Academic Advising Dean

Noel Ayoub, Pamela Basto, Winston Becker, Benjamin Belai, Arthur Brant, Ryan Brewster, Christopher Calkins, Ritika Dutta, Cordelia Erickson-Davis, Rami Ezzibdeh, Joy He, Vivian Hua, Galym Imanbayev, Lauren Joseph, Emily Keamy-Minor, Lily Kim, Steven Losorelli, Pamela Meza, Jung Gi Min, Peter Moon, Justin Norden, Benjamin Ober-Reynolds, Stacie Ong, Tyler Prestwood, Julia Ransohoff, Suhas Rao, Hannah Rasmussen, Felicia Reinitz, Matthew Schoen, Madeleine Scott, Navika Shukla, Gerald Tiu, Pavin Trinh, Silvia Vaca, Yi Zhang

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)
- Molecular and Genetic Medicine (Fellowship Program)

Publications

PUBLICATIONS

- **ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.** *Clinical colorectal cancer*
Reid, T. R., Abrouk, N., Caroen, S., Oronsky, B., Stirn, M., Larson, C., Beale, K., Knox, S. J., Fisher, G.
2022
- **ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Kiess, A. P., Hobbs, R. F., Bednarz, B., Knox, S. J., Meredith, R., Escorcía, F. E.
2022; 113 (4): 719-726
- **Basics of Physics and Radiobiology for Radiopharmaceutical Therapies.** *Practical radiation oncology*
English, K. K., Knox, S., Graves, S. A., Kiess, A. P.
2022; 12 (4): 289-293
- **ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees.** *International journal of radiation oncology, biology, physics*
Kiess, A. P., Hobbs, R. F., Bednarz, B., Knox, S. J., Meredith, R., Escorcía, F. E.
2022
- **Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer.** *Drugs in R&D*
Jayachandran, P., Knox, S. J., Garcia-Cremades, M., Savic, R. M.
2021
- **The Radiobiology of Radiopharmaceuticals.** *Seminars in radiation oncology*
Morris, Z. S., Wang, A. Z., Knox, S. J.
2021; 31 (1): 20–27
- **Locally administered heparin-binding epidermal growth factor-like growth factor reduces radiation-induced oral mucositis in mice.** *Scientific reports*
Chen, J., Bekale, L. A., Khomtchouk, K. M., Xia, A., Cao, Z., Ning, S., Knox, S. J., Santa Maria, P. L.
2020; 10 (1): 17327
- **Just eat it: A review of CD47 and SIRP-alpha antagonism.** *Seminars in oncology*
Oronsky, B., Carter, C., Reid, T., Brinkhaus, F., Knox, S. J.
2020
- **TGF-Beta: A master immune regulator.** *Expert opinion on therapeutic targets*
Larson, C., Oronsky, B., Carter, C. A., Oronsky, A., Knox, S. J., Sher, D., Reid, T. R.
2020
- **A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., Halpenny, D. F., Reddy, S. A., Vado, K. P., McCabe, D., Ramirez, K. A., Macri, M., Schwarzenberger, et al
2020
- **Locally advanced rectal cancer: The past, present, and future.** *Seminars in oncology*
Oronsky, B., Reid, T., Larson, C., Knox, S. J.
2020
- **Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.** *Melanoma management*
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., Knox, S. J.
2020; 7 (1): MMT36

- **Development of a biodosimeter for radiation triage using novel blood protein biomarker panels in humans and non-human primates** *INTERNATIONAL JOURNAL OF RADIATION BIOLOGY*
Balog, R. P., Bacher, R., Chang, P., Greenstein, M., Jammalamadaka, S., Javitz, H., Knox, S. J., Lee, S., Lin, H., Shaler, T., Shura, L., Stein, P., Todd, et al
2020; 96 (1): 22–34
- **Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.** *Seminars in oncology*
Oronsky, B. n., Knox, S. n., Cabrales, P. n., Oronsky, A. n., Reid, T. R.
2020
- **Harnessing genome-wide association studies to minimize adverse radiation-induced side effects.** *Radiation oncology journal*
Benitez, C. M., Knox, S. J.
2020
- **A Review of Newly Diagnosed Glioblastoma.** *Frontiers in oncology*
Oronsky, B., Reid, T. R., Oronsky, A., Sandhu, N., Knox, S. J.
2020; 10: 574012
- **High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer.** *Journal of extracellular vesicles*
Morales-Kastresana, A., Musich, T. A., Welsh, J. A., Telford, W., Demberg, T., Wood, J. C., Bigos, M., Ross, C. D., Kachynski, A., Dean, A., Felton, E. J., Van Dyke, J., Tigges, et al
2019; 8 (1): 1597603
- **INTRADETRUSOR IPSC-DERIVED HUMAN PROGENITOR SMOOTH MUSCLE CELLS IN A ROWETT NUDE RAT MODEL OF RADIATION CYSTITIS**
Dobberfuhl, A. D., Briggs, M. A., Wallace, S. L., Wen, Y., Zhou, Y., Graves, E. E., Diaz, E. C., Knox, S. J., Chen, B.
LIPPINCOTT WILLIAMS & WILKINS.2019: E155
- **Outcomes and Characteristics of Patients Treated with Emergent Palliative Radiation Therapy** *PRACTICAL RADIATION ONCOLOGY*
Grade, M., Koenig, J., Qian, Y., Sandhu, N., Liu, Y., Turner, B., von Eyben, R., Knox, S., Dudley, S.
2019; 9 (2): E203–E209
- **Development of a biodosimeter for radiation triage using novel blood protein biomarker panels in humans and non-human primates.** *International journal of radiation biology*
Balog, R. P., Bacher, R., Chang, P., Greenstein, M., Jammalamadaka, S., Javitz, H., Knox, S. J., Lee, S., Lin, H., Shaler, T., Shura, L., Stein, P., Todd, et al
2019: 1–13
- **High Fidelity Detection and Sorting of Nanoscale Vesicles in Viral Disease and Cancer** *J Extrac Ves*
Morales-Kastresana, A., Musich, T., Welsh, J. A., Telford, W., Demberg, T., Wood, J., Felton, E., Bigos, M., Ross, C., Kachynski, A., Dean, A., Dyke, J., Tigges, et al
2019
- **Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer.** *Translational oncology*
Knox, S. J., Jayachandran, P. n., Keeling, C. A., Stevens, K. J., Sandhu, N. n., Stamps-DeAnda, S. L., Savic, R. n., Shura, L. n., Buyyounouski, M. K., Grimes, K. n.
2019; 12 (11): 1525–31
- **Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.** *Cureus*
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., Knox, S. J.
2018; 10 (12): e3723
- **Outcomes and characteristics of patients treated with emergent palliative radiotherapy.** *Practical radiation oncology*
Grade, M., Koenig, J., Qian, Y., Sandhu, N., Liu, Y., Turner, B., von Eyben, R., Knox, S., Dudley, S.
2018
- **Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up** *CUREUS*
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., Knox, S. J.
2018; 10 (12)

- **INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRx-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES**
Kim, M., Parmar, H., Aryal, M., Schipper, M., Devasia, T., Kesari, S., Morikawa, A., Spratt, D., Junck, L., Hayman, J., Lawrence, T., Tsien, C., Aiken, et al
OXFORD UNIV PRESS INC.2018: 63
- **Initial Clinical and Advanced Imaging Outcomes from a Multi-Institutional Phase I Dose-Escalation Trial of RRx-001 Plus Whole Brain Radiation for Patients with Brain Metastases**
Kim, M. M., Parmar, H., Aryal, M. P., Schipper, M., Devasia, T. P., Kesari, S., Morikawa, A., Spratt, D. E., Junck, L., Hayman, J. A., Lawrence, T. S., Tsien, C., Aiken, et al
ELSEVIER SCIENCE INC.2018: E266
- **Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017** *CLINICAL CANCER RESEARCH*
Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Browns, M., Knox, S., Bristow, R., Spellman, et al
2018; 24 (15): 3500–3509
- **Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) plus ipilimumab (ipi) plus external beam radiotherapy (RT) in patients with metastatic melanoma.**
Postow, M. A., Knox, S., Goldman, D., Panageas, K., Halpenny, D., McCabe, D., Macri, M. J., Schwarzenberger, P., Ricciardi, T., Ryan, A., Venhaus, R., Barker, C.
AMER SOC CLINICAL ONCOLOGY.2018
- **A note on improved statistical approaches to account for pseudoprogression** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Abrouk, N., Oronsky, B., Caroen, S., Ning, S., Knox, S., Peehl, D.
2018; 81 (3): 621–26
- **Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases** *Oxford Univ Press Inc.*
Kim, M.
2018; 20 (63)
- **The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry**
Zhao, H., Ning, S., Nolley, R., Scicinski, J., Oronsky, B., Knox, S. J., Peehl, D. M.
AMER ASSOC CANCER RESEARCH.2017
- **High Dose Gamma Radiation Selectively Reduces GABAA-slow Inhibition.** *Cureus*
Dagne, B. A., Sunay, M. K., Cayla, N. S., Ouyang, Y., Knox, S. J., Giffard, R. G., Adler, J. R., Maciver, B.
2017; 9 (3)
- **The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry** *CLINICAL EPIGENETICS*
Zhao, H., Ning, S., Nolley, R., Scicinski, J., Oronsky, B., Knox, S. J., Peehl, D. M.
2017; 9
- **RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*
Oronsky, B., Paulmurugan, R., Foygel, K., Scicinski, J., Knox, S. J., Peehl, D., Zhao, H., Ning, S., Cabrales, P., Summers, T. A., Reid, T. R., Fitch, W. L., Kim, et al
2017; 26 (1): 109-119
- **Phase I Trial: SABR and Ipilimumab-Letter** *CLINICAL CANCER RESEARCH*
Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.
2017; 23 (1): 320
- **High Dose Gamma Radiation Selectively Reduces GABAA-slow Inhibition** *Cureus*
Dagne, B. A., Sunay, M. K., Cayla, N. S., Ouyang, Y., Knox, S. J., Giffard, R. G., Adler, J. D., MacIver, M. B.
2017: e1076
- **Alteration of Interneuron Immunoreactivity and Autophagic Activity in Rat Hippocampus after Single High-Dose Whole-Brain Irradiation.** *Cureus*

- Ouyang, Y. B., Ning, S. n., Adler, J. R., Maciver, B. n., Knox, S. J., Giffard, R. n.
2017; 9 (6): e1414
- **Phase I Trial: SABR and Ipilimumab-Letter.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.
2017; 23 (1): 320
 - **A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.** *International journal of radiation oncology, biology, physics*
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., Knox, S. J.
2016; 96 (3): 578-588
 - **RRx-001, A novel dinitroazetidine radiosensitizer** *INVESTIGATIONAL NEW DRUGS*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 34 (3): 371-377
 - **Merkel cell carcinoma: demographic, clinical, and treatment parameters of prognostic significance** *JOURNAL OF RADIATION ONCOLOGY*
Fu, M. A., Osmundson, E. C., von Eyben, R., Knox, S. J., Kapp, D. S.
2016; 5 (2): 205–12
 - **Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.** *Translational oncology*
Kim, M. M., Parmar, H., Cao, Y., Pramanik, P., Schipper, M., Hayman, J., Junck, L., Mammoser, A., Heth, J., Carter, C. A., Oronsky, A., Knox, S. J., Caroen, et al
2016; 9 (2): 108-113
 - **Rockets, Radiosensitizers, and RRx-001: An Origin Story Part I** *DISCOVERY MEDICINE*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 115: 173-180
 - **Rockets, radiosensitizers, and RRx-001: an origin story part I.** *Discovery medicine*
Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., Bednarski, M., Knox, S.
2016; 21 (115): 173-180
 - **Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.** *Neuro-oncology*
Kim, M. M., Parmar, H. n., Cao, Y. n., Knox, S. J., Oronsky, B. n., Scicinski, J. n., Lawrence, T. S., Lao, C. D.
2016; 18 (3): 455–56
 - **Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.** *Oncotarget*
Zhao, H., Ning, S., Scicinski, J., Oronsky, B., Knox, S. J., Peehl, D. M.
2015; 6 (41): 43172-43181
 - **NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001** *REDOX BIOLOGY*
Scicinski, J., Oronsky, B., Ning, S., Knox, S., Peehl, D., Kim, M. M., Langecker, P., Fanger, G.
2015; 6: 1-8
 - **Predictors of clinical response to immunotherapy with or without radiotherapy** *JOURNAL OF RADIATION ONCOLOGY*
Hiniker, S. M., Maecker, H. T., Knox, S. J.
2015; 4 (4): 339–45
 - **NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.** *Redox biology*
Scicinski, J., Oronsky, B., Ning, S., Knox, S., Peehl, D., Kim, M. M., Langecker, P., Fanger, G.
2015; 6: 1-8
 - **RRx-001, a novel first in class epigenetic modulator, "episensitizes" colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 "ROCKET" study**
Reid, T., Carney, J., Beale, K., Clayton, C., Nguyen, H., Cho-Phan, C., Stirn, M., Ning, S., Knox, S., Oronsky, B., Scicinski, J., Caroen, S., Parker, et al
AMER ASSOC CANCER RESEARCH.2015

- **Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study** *LANCET ONCOLOGY*
Reid, T., Oronsky, B., Scicinski, J., Scribner, C. L., Knox, S. J., Ning, S., Peehl, D. M., Korn, R., Stirn, M., Carter, C. A., Oronsky, A., Taylor, M. J., Fitch, et al
2015; 16 (9): 1133-1142
- **Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.** *Oncotarget*
Ning, S., Sekar, T. V., Scicinski, J., Oronsky, B., Peehl, D. M., Knox, S. J., Paulmurugan, R.
2015; 6 (25): 21547-21556
- **The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.** *Redox biology*
Scicinski, J., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Ning, S., Knox, S., Oronsky, B., Caroen, S., Parker, C., Fanger, G., Reid, T.
2015; 5: 422-?
- **RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy**
Zhao, H., Ning, S., Scicinski, J., Oronsky, B., Knox, S., Peehl, D. M.
AMER ASSOC CANCER RESEARCH.2015
- **From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.** *Malaria journal*
Yalcin, O., Oronsky, B., Carvalho, L. J., Kuypers, F. A., Scicinski, J., Cabrales, P.
2015; 14: 218
- **29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Hurwitz, A. A., Lee, S., Knox, S., Kohrt, H., Verdeil, G., Romano, E., Margolin, K., Urba, W. J., Speiser, D. E.
2015; 3
- **CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma** *CLINICAL CANCER RESEARCH*
Knox, S. J., Levy, R.
2015; 21 (3): 493-94
- **Predictors of clinical response to immunotherapy with or without radiotherapy.** *Journal of radiation oncology*
Hiniker, S. M., Maecker, H. T., Knox, S. J.
2015; 4: 339-345
- **Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma**
Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., Advani, R., Kim, Y. H., Hoppe, R. T., Knox, S. J., Wapnir, I., Tibshirani, R. J., Levy, et al
AMER SOC HEMATOLOGY.2014
- **Immunotherapy and radiation.** *Seminars in oncology*
Hiniker, S. M., Knox, S. J.
2014; 41 (6): 702-713
- **Novel Human Radiation Exposure Biomarker Panel Applicable for Population Triage** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Bazan, J. G., Chang, P., Balog, R., D'Andrea, A., Shaler, T., Lin, H., Lee, S., Harrison, T., Shura, L., Schoen, L., Knox, S. J., Cooper, D. E.
2014; 90 (3): 612-619
- **Novel human radiation exposure biomarker panel applicable for population triage.** *International journal of radiation oncology, biology, physics*
Bazan, J. G., Chang, P., Balog, R., D'Andrea, A., Shaler, T., Lin, H., Lee, S., Harrison, T., Shura, L., Schoen, L., Knox, S. J., Cooper, D. E.
2014; 90 (3): 612-9
- **Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice**
Ning, S., Sekar, T., Paulmurugan, R., Scicinski, J., Oronsky, B., Peehl, D., Knox, S. J.
AMER ASSOC CANCER RESEARCH.2014
- **A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent.**
Reid, T. R., Oronsky, B., Infante, J. R., Burris, H. A., Scribner, C., Knox, S., Stephens, J. L., Fanger, G., Scicinski, J.
AMER SOC CLINICAL ONCOLOGY.2014

- **Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.** *Biochemical and biophysical research communications*
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Knox, S. J.
2014; 447 (3): 537-542
- **The Implications of Hyponitroxia in Cancer** *TRANSLATIONAL ONCOLOGY*
Oronsky, B., Fanger, G. R., Oronsky, N., Knox, S., Scicinski, J.
2014; 7 (2): 167-173
- **The implications of hyponitroxia in cancer** *Translational Oncology*
Oronsky, B., Fanger, G., Oronsky, N., Knox, S. J., Scicinski, J.
2014; 7 (2): 167-173
- **Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.** *Case reports in oncology*
Reid, T., Dad, S., Korn, R., Oronsky, B., Knox, S., Scicinski, J.
2014; 7 (1): 79-85
- **Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment** *ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY*
Oronsky, B., Oronsky, N., Knox, S., Fanger, G., Scicinski, J.
2014; 14 (8): 1121-1127
- **Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy** *Biochemical and Biophysical Research Communications*
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Knox, S. J.
2014; 447 (3): 537-542
- **Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients** *Case Reports in Oncology*
Reid, T., Dad, S., Korn, R., Oronsky, G., Knox, S. J., Scicinski, J.
2014; 7 (1): 79-85
- **Topical hypochlorite ameliorates NF-kappa B-mediated skin diseases in mice** *JOURNAL OF CLINICAL INVESTIGATION*
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. J., Kim, S. K.
2013; 123 (12): 5361-5370
- **Radioprotection and Cell Cycle Arrest of Intestinal Epithelial Cells by Darinaparsin, a Tumor Radiosensitizer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tian, J., Doi, H., Saar, M., Santos, J., Li, X., Peehl, D. M., Knox, S. J.
2013; 87 (5): 1179-1185
- **Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line** *CLINICAL IMMUNOLOGY*
Parker, J. J., Jones, J. C., Strober, S., Knox, S. J.
2013; 148 (1): 44-55
- **Phase I Study of a Modified Regimen of (90)Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+Non-Hodgkin Lymphoma** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Vaklavas, C., Meredith, R. F., Shen, S., Knox, S. J., Micallef, I. N., Shah, J. J., LoBuglio, A. F., Forero-Torres, A.
2013; 28 (5): 370-379
- **Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent.**
Reid, T., Infante, J. R., Paul, A., Burris, H. A., Oronsky, B., Scribner, C., Knox, S., Stephens, J., Santini, J., Scicinski, J.
AMER ASSOC CANCER RESEARCH.2013
- **Activity observed in a phase I dose escalation trial of the hypoxia-activated, NO prodrug, RRx001**
Reid, T. R., Infante, J. R., Burris, H. A., Scribner, C., Knox, S., Oronsky, B., Stephens, J. L., Scicinski, J.
AMER SOC CLINICAL ONCOLOGY.2013
- **Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.** *Theranostics*

- Paulmurugan, R., Oronsky, B., Brouse, C. F., Reid, T., Knox, S., Scicinski, J.
2013; 3 (6): 437-447
- **Topical hypochlorite ameliorates NF- κ B-mediated skin diseases in mice** *The Journal of Clinical Investigation*
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. K., Kim, S. K.
2013; 123 (12): 5361-5370
 - **A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy** *TRANSLATIONAL ONCOLOGY*
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., Knox, S. J.
2012; 5 (6): 404-407
 - **The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Reid, T., Knox, S. J., Scicinski, J. J.
2012; 5 (4): 226-229
 - **Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice** *RADIATION RESEARCH*
Ning, S., Budas, G. R., Churchill, E. N., Chen, C., Knox, S. J., Mochly-Rosen, D.
2012; 178 (1): 69-74
 - **Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer** *CLINICAL CANCER RESEARCH*
Tian, J., Zhao, H., Nolley, R., Reese, S. W., Young, S. R., Li, X., Peehl, D. M., Knox, S. J.
2012; 18 (12): 3366-3376
 - **Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Scicinski, J. J., Reid, T., Knox, S.
2012; 5 (3): 133-140
 - **Abscopal Effect in a Patient with Melanoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Hiniker, S. M., Chen, D. S., Knox, S. J.
2012; 366 (21): 2035-2035
 - **Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials** *CANCER RESEARCH*
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Saul, G., Knox, S. J.
2012; 72 (10): 2600-2608
 - **RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors**
Scicinski, J., Oronsky, B., Ning, S., Minchinton, A., Knox, S.
AMER ASSOC CANCER RESEARCH.2012
 - **Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review** *TRANSLATIONAL ONCOLOGY*
Oronsky, B. T., Knox, S. J., Scicinski, J. J.
2012; 5 (2): 66-71
 - **Phase I, Multicenter, Open Label, Dose Escalation of (90)yttrium-Ibritumomab' Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+B-Cell Lymphoma**
Vaklavas, C., Meredith, R. F., Knox, S. J., Wiseman, G., Witzig, T. E., Micallef, I. N., Lobuglio, A. F., Forero, A.
AMER SOC HEMATOLOGY.2011: 716-717
 - **Six degrees of separation: the oxygen effect in the development of radiosensitizers.** *Translational oncology*
Oronsky, B. T., Knox, S. J., Scicinski, J.
2011; 4 (4): 189-198
 - **Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials**
Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Saul, G., Knox, S. J.
AMER ASSOC CANCER RESEARCH.2011
 - **Anti-tumor and radiosensitization activities of the iron chelator HDP44mT are mediated by effects on intracellular redox status** *CANCER LETTERS*

- Tian, J., Peehl, D. M., Zheng, W., Knox, S. J.
2010; 298 (2): 231-237
- **Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas**
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T., Horner, T. J., Williams, V. C., Lin, T. S., Vleisides, C., Knox, S. J., Wahl, et al
AMER SOC HEMATOLOGY.2010: 1615
 - **In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., Levy, et al
2010; 28 (28): 4324-4332
 - **Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats** *CANCER RESEARCH*
Ning, S., Tian, J., Marshall, D. J., Knox, S. J.
2010; 70 (19): 7591-7599
 - **SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tian, J., Ning, S., Knox, S. J.
2010; 78 (1): 230-236
 - **Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Tian, J., Peehl, D. M., Knox, S. J.
2010; 25 (4): 439-448
 - **I-131-Tositumomab (Bexxar (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma** *MOLECULAR IMAGING AND BIOLOGY*
Iagaru, A., Mitra, E. S., Ganjoo, K., Knox, S. J., Goris, M. L.
2010; 12 (2): 198-203
 - **Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma** *JOURNAL OF NUCLEAR MEDICINE*
Shen, S., Forero, A., Meredith, R. F., Shah, J. J., Knox, S. J., Wiseman, G. A., Usrey, M. E., LoBuglio, A. F.
2010; 51 (1): 150-157
 - **Impact of Radiation on Immunotherapy Targets** *24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer*
Jones, J. C., Knox, S. J.
LIPPINCOTT WILLIAMS & WILKINS.2009: 971-72
 - **Lanreotide promotes apoptosis and is not radioprotective in GH3 cells** *ENDOCRINE-RELATED CANCER*
Ning, S., Knox, S. J., Harsh, G. R., Culler, M. D., Katznelson, L.
2009; 16 (3): 1045-1055
 - **Identification of Novel Radiation Induced Immune Signaling Changes in Antigen Presenting Cells** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Parker, J. J., Jones, J. C., Strober, S., Knox, S.
ELSEVIER SCIENCE INC.2009: S545-S545
 - **Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Bhattacharyya, R. S., Husbeck, B., Feldman, D., Knox, S. J.
2008; 72 (3): 935-940
 - **Risks to normal tissues from radionuclide therapy** *SEMINARS IN NUCLEAR MEDICINE*
Meredith, R., Wessels, B., Knox, S.
2008; 38 (5): 347-357

- **Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo** *MOLECULAR CANCER THERAPEUTICS*
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., Knox, S. J.
2008; 7 (6): 1569-1578
- **CNTO 95, a monoclonal antibody against alpha v integrins, enhances the therapeutic efficacy of fractionated radiation therapy in vivo.**
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., Knox, S. J.
AMER ASSOC CANCER RESEARCH.2007: 3537S-3537S
- **MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy?** *JOURNAL OF NUCLEAR MEDICINE*
Sgouros, G., Knox, S. J., Joiner, M. C., Morgan, W. F., Kassis, A. I.
2007; 48 (10): 1683-1691
- **Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients** *CANCER*
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., Begley, C. G.
2007; 110 (3): 477-488
- **Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis** *RADIATION RESEARCH*
Ning, S., Chen, Z., Dirks, A., Husbeck, B., Hsu, M., Bedogni, B., O'Neill, M., Powell, M. B., Knox, S. J.
2007; 168 (1): 125-133
- **Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma** *BLOOD*
Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K. M., Lisby, et al
2007; 109 (11): 4655-4662
- **Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action** *MOLECULAR CANCER THERAPEUTICS*
Husbeck, B., Bhattacharyya, R. S., Feldman, D., Knox, S. J.
2006; 5 (8): 2078-2085
- **Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Ning, S., Knox, S. J.
2006; 65 (2): 493-498
- **Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., Hernandez, C., Zhu, H. J., Zhang, Y., Nangiana, J. S., Shan, J. S., Roberts, K., Knox, S. J.
2006; 21 (3): 243-256
- **Radiation sensitization with redox modulators: A promising approach** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Rosenberg, A., Knox, S.
2006; 64 (2): 343-354
- **Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells** *PROSTATE*
Husbeck, B., Nonn, L., Peehl, D. M., Knox, S. J.
2006; 66 (2): 218-225
- **Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation** *CANCER*
Patel, D. A., Kochanski, J., Suen, A. W., Fajardo, L. F., Hancock, S. L., Knox, S. J.
2006; 106 (3): 718-725
- **Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma** *Systemics Targeted Radionuclide Therapy Symposium (STaRT)*
Meredith, R. F., Knox, S. J.

ELSEVIER SCIENCE INC.2006: S15–S22

- **A preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular or transformed non-Hodgkin's lymphoma (NHL)** *47th Annual Meeting of the American-Society-of-Hematology*
Forero-Torres, A., Shah, J., Besh, S., Knox, S., Micallef, I., Wiseman, G., Witzig, T., Lobuglio, A., Shen, S., Goris, M., Connor, J., Meredith, R.
AMER SOC HEMATOLOGY.2005: 280B–280B
- **Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., KROLL, S., Wahl, R. L.
AMER SOC CLINICAL ONCOLOGY.2005: 7985–93
- **Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*
Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., KROLL, S., Goldsmith, S. J., Coleman, M.
2005; 23 (30): 7565-7573
- **Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab** *BLOOD*
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., Capizzi, R. L.
2005; 105 (12): 4576-4582
- **Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing** *FREE RADICAL BIOLOGY AND MEDICINE*
Husbeck, B., Peehl, D. M., Knox, S. J.
2005; 38 (1): 50-57
- **Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia** *CANCER RESEARCH*
Ning, S. C., Hartley, C., Molineux, G., Knox, S. J.
2005; 65 (1): 284-290
- **The radioisotope contributes significantly to the activity of radioimmunotherapy** *CLINICAL CANCER RESEARCH*
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., Wahl, R. L., KROLL, S., Coleman, M., Goris, M., Levy, R., Knox, S. J.
2004; 10 (23): 7792-7798
- **Tositumomab and iodine I 131 tositumomab (the BEXXAR (R) therapeutic regimen) shows efficacy in elderly patients (pts) with relapsed/refractory low-grade (LG), follicular, and transformed non-Hodgkin's lymphoma (NHL).**
Gregory, S. A., Zelenetz, A., Knox, S. J., Vose, J., Leonard, J. P., Kaminski, M.
AMER SOC HEMATOLOGY.2004: 719A-720A
- **Tositumomab and iodine I 131 tositumomab (The BEXXAR (R) therapeutic regimen) produced ongoing, durable remissions of more than 5 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy.**
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T. A., Kroll, S., Wahl, R. L., Knox, S. J., Vose, J. M.
AMER SOC HEMATOLOGY.2004: 720A
- **Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier** *PHARMACEUTICAL RESEARCH*
Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L. Y., Choi, S., DeChene, N. E., Doede, T., Huang, L., Pease, J. S., Shen, Z. M., Knox, S. J., Cleland, J. L.
2004; 21 (10): 1880-1885
- **Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Ning, S. C., Knox, S. J.
2004; 60 (1): 197-203
- **Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors** *RADIATION RESEARCH*
Maxim, P. G., Carson, J. J., Ning, S. C., Knox, S. J., Boyer, A. L., Hsu, C. P., Benaron, D. A., Walleczek, J.
2004; 162 (2): 185-193

- **Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer** *10th Conference on Cancer Therapy with Antibodies and Immunoconjugates*
Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., Street, H., Nangiana, J., Shan, J., Goris, M.
MARY ANN LIEBERT INC.2004: 528–28
- **Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Hernandez, M. C., Knox, S. J.
2004; 59 (5): 1274-1287
- **Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma** *BLOOD*
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., Sims, R. B., Ghalie, R. G., Shen, et al
2004; 104 (1): 227-236
- **Dosimetry model for radioactivity localized to intestinal mucosa** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Fisher, D., Rajon, D., Breitz, H., Goris, M., Bolch, W., Knox, S.
2004; 19 (3): 293-307
- **A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Li, L. Y., Wartchow, C. A., Danthi, S. N., Shen, Z. M., DeChene, N., PEASE, J., Choi, H. S., Doede, T., Chu, P., Ning, S. C., Lee, D. Y., Bednarski, M. D., Knox, et al
2004; 58 (4): 1215-1227
- **HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma** *65th Annual Meeting of the Society-for-Investigative-Dermatology*
Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Gniadecki, R., Duvic, M., Cooper, K., Jensen, P., Baadsgaard, et al
NATURE PUBLISHING GROUP.2004: A57–A57
- **Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells** *RADIATION RESEARCH*
Li, L. Y., Steinauer, K. K., Dirks, A. J., Husbeck, B., Gibbs, I., Knox, S. J.
2003; 160 (6): 617-621
- **Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin)** *SEMINARS IN ONCOLOGY*
Hernandez, M. C., Knox, S. J.
2003; 30 (6): 6-10
- **Higher doses of Rituxan (R) alter pharmacokinetics and biodistribution of Zevalin (R) but may increase responses; a preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular/transformed non-Hodgkin's lymphoma.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Forero-Torres, A., Besh, S., Knox, S., Micallef, I., Wiseman, G., Witzig, T., Lobuglio, A., Shen, S., Goris, M., CARPENTER, M., Meredith, R.
AMER SOC HEMATOLOGY.2003: 408A–408A
- **Re-treatment with Tositumomab and Iodine I131 Tositumomab (the BEXXAR (R) therapeutic regimen) in patients with non-Hodgkin's lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen.**
Kaminski, M. S., Knox, S. J., Radford, J., Gregory, S. A., Leonard, J. P.
AMER SOC HEMATOLOGY.2003: 407A
- **The BEXXAR (R) therapeutic regimen (Tositumomab and Iodine I 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naive disease.**
Coleman, M., Kaminski, M. S., Knox, S. J., Zelenetz, A. D., Vose, J. M.
AMER SOC HEMATOLOGY.2003: 29A
- **The BEXXAR (R) therapeutic regimen (Tositumomab and iodine I 131 tositumomab) can be safely administered to patients over the age of 70.**
Gregory, S. A., Zelenetz, A. D., Knox, S. J., Vase, J. M., Kaminski, M. S.
AMER SOC HEMATOLOGY.2003: 409A
- **Assessment of treatment-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with tositumomab and iodine-131 tositumomab (the BEXXAR (R) therapeutic regimen).**

- Bennett, J. M., Kaminski, M. S., Knox, S. J., Zelenetz, A. D., Leonard, J. P., Vose, J. M., Horning, S.
AMER SOC HEMATOLOGY.2003: 30A
- **HuMax-CD4, a fully human monoclonal antibody: Early results of an ongoing phase II trial in cutaneous T cell lymphoma**
Obitz, E., Kim, Y. H., Iversen, L., Osterborg, A., Jensen, P., Baadsgaard, O., Knox, S. J.
AMER SOC HEMATOLOGY.2003: 645A
 - **Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR (R)) with Tositumomab alone in patients with relapsed or refractory low-grade (LG) or transformed low grade (T-LG) Non-Hodgkin's Lymphoma (NHL). 45th Annual Meeting and Exhibition of the American-Society-of-Hematology**
Davis, T., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Wahl, R., Coleman, M., Goris, M., Levy, R., Knox, S.
AMER SOC HEMATOLOGY.2003: 405A-406A
 - **Cell surface receptor-targeted dextran-coated liposomes for the treatment of solid tumors. 226th National Meeting of the American-Chemical-Society**
Wartchow, C. A., Alters, S. E., Choi, S., DeChene, N. E., Doede, T., Huang, L. N., Pease, J. S., Shen, Z. M., Li, L. Y., Cleland, J. L., Knox, S. J.
AMER CHEMICAL SOC.2003: U468-U468
 - **Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma HUMAN PATHOLOGY**
Yuen, A. R., Higgins, J. P., Baker, R., Kamel, O. W., Warnke, R. A., Knox, S. J.
2003; 34 (4): 381-384
 - **Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).**
Meredith, R., Shen, S., Breitz, H., Fisher, D., Goris, M., Knox, S., Hankins, J., Vose, J., Picozzi, V.
SOC NUCLEAR MEDICINE INC.2002: 116P-117P
 - **Synthesis of multivalent nanoparticles for use in targeting vascular receptors.**
Danthi, S. N., Li, L. Y., Ning, S. C., Choi, H. S., Wartchow, C. A., Lee, D., Knox, S. J., Bednarski, M. D.
AMER CHEMICAL SOC.2002: A109-A109
 - **Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line CELL DEATH AND DIFFERENTIATION**
Armstrong, J. S., Steinauer, K. K., Hornung, B., Irish, J. M., Lecane, P., Birrell, G. W., Peehl, D. M., Knox, S. J.
2002; 9 (3): 252-263
 - **The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation RADIATION RESEARCH**
Ning, S. C., Laird, D., Cherrington, J. M., Knox, S. J.
2002; 157 (1): 45-51
 - **Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS**
Armstrong, J. S., Hornung, B., Lecane, P., Jones, D. P., Knox, S. J.
2001; 289 (5): 973-978
 - **Radioimmunotherapy of B-cell NHL. Current pharmaceutical biotechnology**
Meredith, R. F., Knox, S. J.
2001; 2 (4): 327-339
 - **Incidence of myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxar (TM).**
Bennett, J. M., Zelenetz, A. D., Press, O. W., Vose, J. M., Radford, J. A., Knox, S. J., Wilkinson, M., Schwartz, R. S., Kaminski, M. S., Capizzi, R.
AMER SOC HEMATOLOGY.2001: 335A
 - **Results of a randomized study of Bexxar (TM) (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL).**
Davis, T. A., Kaminski, M. S., Leonard, J. P., Gregory, S. A., Wahl, R., Hsu, F. J., Wilkinson, M., Frankel, Serafini, A., Zelenetz, A. D., Kroll, S., Coleman, M., Levy, R., et al
AMER SOC HEMATOLOGY.2001: 843A
 - **Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas JOURNAL OF CLINICAL ONCOLOGY**

- Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., KROLL, S., Wahl, R. L., Knox, S. J., Vose, et al
2001; 19 (19): 3918-3928
- **Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization** *EXPERIMENTAL CELL RESEARCH*
Armstrong, J. S., Steinauer, K. K., French, J., Killoran, P. L., Walleczek, J., Kochanski, J., Knox, S. J.
2001; 262 (2): 170-179
 - **Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Murtha, A. D., Knox, S. J., Hoppe, R. T., Rupnow, B. A., Hanson, J.
2001; 49 (1): 3-15
 - **Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Steinauer, K. K., Gibbs, I., Ning, S. C., French, J. N., Armstrong, J., Knox, S. J.
2000; 48 (2): 325-328
 - **Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis** *CANCER RESEARCH*
Williams, S. S., French, J. N., Gilbert, M., Rangaswami, A. A., Walleczek, J., Knox, S. J.
2000; 60 (16): 4358-4361
 - **Introduction** *Seminars in radiation oncology*
Knox, S. J.
2000; 10 (2): 71-2
 - **Clinical radioimmunotherapy** *SEMINARS IN RADIATION ONCOLOGY*
Knox, S. J., Meredith, R. F.
2000; 10 (2): 73-93
 - **Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., Kaminski, M. S.
2000; 18 (6): 1316-1323
 - **Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer** *CLINICAL CANCER RESEARCH*
Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., ADAMS, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, et al
2000; 6 (2): 406-414
 - **Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Breitz, H. B., Fisher, D. R., Goris, M. L., Knox, S., Ratliff, B., Murtha, A. D., Weiden, P. L.
1999; 14 (5): 381-395
 - **G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation** *RADIATION RESEARCH*
Ning, S. C., Knox, S. J.
1999; 151 (6): 659-669
 - **The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy** *APOPTOSIS*
Rupnow, B. A., Knox, S. J.
1999; 4 (2): 115-143
 - **Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system** *RADIOTHERAPY AND ONCOLOGY*
Ning, S. C., Yu, N., Brown, D. M., Kanekal, S., Knox, S. J.
1999; 50 (2): 215-223

- **Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor** *CANCER LETTERS*
Rupnow, B. A., Murtha, A. D., Chen, E., Knox, S. J.
1998; 127 (1-2): 211-219
- **Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy** *CANCER RESEARCH*
Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., Knox, S. J.
1998; 58 (9): 1779-1784
- **Pretargeted Radioimmunotherapy (TM) with antibody-streptavidin and Y-90 DOTA-Biotin (Avicidin (R)): Result of a dose escalation study.**
Breitz, H., Knox, S., Weiden, P., Goris, M., Murtha, A., Bryan, J., Axworthy, D., Seiler, C., Su, F. M., Beaumier, P., Reno, J.
SOC NUCLEAR MEDICINE INC.1998: 71P-71P
- **p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts** *CELL DEATH AND DIFFERENTIATION*
Rupnow, B. A., Alarcon, R. M., Giaccia, A. J., Knox, S. J.
1998; 5 (2): 141-147
- **Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Ning, S. C., Shui, C. X., Khan, W. B., Benson, W., Lacey, D. L., Knox, S. J.
1998; 40 (1): 177-187
- **Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts** *6th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*
Ning, S. C., Trisler, K., Wessels, B. W., Knox, S. J.
WILEY-BLACKWELL.1997: 2519-28
- **A prospective study of radiation therapy-associated thrombocytopenia** *BLOOD*
Knox, S. J., Varghese, A., Khan, W., Chen, E., MacManus, M., Ray, G., Lee, K., Lamborn, K. R.
1997; 90 (10): 4237-4238
- **Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor** *RADIATION RESEARCH*
Khan, W. B., Shui, C. X., Ning, S. C., Knox, S. J.
1997; 148 (3): 248-253
- **Influence of Bcl-2 overexpression on Na⁺/K⁺-ATPase pump activity: Correlation with radiation-induced programmed cell death** *JOURNAL OF CELLULAR PHYSIOLOGY*
Gilbert, M., Knox, S.
1997; 171 (3): 299-304
- **Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model** *BLOOD*
MacManus, M., Lamborn, K., Khan, W., Varghese, A., Graef, L., Knox, S.
1997; 89 (7): 2303-2310
- **Hematological toxicity in radioimmunotherapy is predicted both by the computed absorbed whole body dose (cGY) and by the administered dose (mCi)**
Marquez, S. D., Knox, S. J., Trisler, K. D., Goris, M. L.
PERGAMON-ELSEVIER SCIENCE LTD.1997: 327
- **Low dose rate radiation favors apoptosis as a mechanism of cell death**
Murtha, A. D., Rupnow, B., Knox, S. J.
PERGAMON-ELSEVIER SCIENCE LTD.1997: 242
- **Apoptotic potential and cell sensitivity to fractionated radiotherapy.**
Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., Knox, S. J.
PERGAMON-ELSEVIER SCIENCE LTD.1997: 179
- **Randomized controlled study of I-131-Anti-B1 versus unlabeled-Anti-B1 monoclonal antibody in patients with chemotherapy refractory low grade non-Hodgkin's lymphoma**
Knox, S. J., Goris, M. L., Davis, T. A., Trisler, K. D., Saal, J., Levy, R.

PERGAMON-ELSEVIER SCIENCE LTD.1997: 326

- **Modulation of c-myc activity and apoptosis in vivo** *CANCER RESEARCH*
Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., Giaccia, A. J.
1996; 56 (19): 4315-4319
- **Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody** *CLINICAL CANCER RESEARCH*
Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., Ning, S. C., Becker, M., Marquez, C., Knox, S.
1996; 2 (8): 1289-1297
- **Association of BCL-2 with membrane hyperpolarization and radioresistance** *JOURNAL OF CELLULAR PHYSIOLOGY*
Gilbert, M. S., Saad, A. H., Rupnow, B. A., Knox, S. J.
1996; 168 (1): 114-122
- **Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel** *RADIOTHERAPY AND ONCOLOGY*
Ning, S., Trisler, K., Brown, D. M., Yu, N. Y., Kanekal, S., Lundsten, M. J., Knox, S. J.
1996; 39 (2): 179-189
- **Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine)** *CELL DEATH AND DIFFERENTIATION*
Gilbert, M. S., Rupnow, B. A., Ramirez, D. A., Trisler, K. D., Knox, S. J.
1996; 3 (2): 215-222
- **Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma** *CLINICAL CANCER RESEARCH*
Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., GRILLOLOPEZ, A., Chinn, P., Varns, C., Ning, S. C., Fowler, S., Deb, N., Becker, et al
1996; 2 (3): 457-470
- **Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody** *BLOOD*
Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., Cornbleet, P. J., Levy, R.
1996; 87 (3): 893-899
- **Overview of studies on experimental radioimmunotherapy.** *Cancer research*
Knox, S. J.
1995; 55 (23): 5832s-5836s
- **(90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma**
Davis, T. A., Goris, M. L., Trisler, K. D., Negrin, R., Liles, T. M., Fowler, S. F., Deb, N., Becker, M., Marquez, C. M., Ning, S., Levy, R., Knox, S.
AMER SOC HEMATOLOGY.1995: 1080-80
- **Radioimmunotherapy of the Non-Hodgkin's Lymphomas.** *Seminars in radiation oncology*
Knox, S. J.
1995; 5 (4): 331-341
- **EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS** *CANCER RESEARCH*
Shui, C. X., Khan, W. B., Leigh, B. R., Turner, A. M., Wilder, R. B., Knox, S. J.
1995; 55 (15): 3431-3437
- **MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Becker, M., Hoppe, R. T., Knox, S. J.
1995; 32 (5): 1445-1449
- **STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION** *RADIATION RESEARCH*
Leigh, B. R., Khan, W., Hancock, S. L., Knox, S. J.
1995; 142 (1): 12-15
- **STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE** *STEM CELLS*
Leigh, B. R., Webb, S., Hancock, S. L., Knox, S. J.
1994; 12 (4): 430-435

- **ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES** *9th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*
Goris, M. L., Knox, S. A., Nielsen, K. R., BOUILLANT, O.
JOHN WILEY & SONS INC.1994: 919-22
- **EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Knox, S. J., Fowler, S., Marquez, C., Hoppe, R. T.
1994; 28 (2): 445-450
- **THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Wilder, R. B., McGann, J. K., SUTHERLAND, W. R., Waller, E. K., Minchinton, A. I., Goris, M. L., Knox, S. J.
1994; 28 (1): 119-126
- **DETERMINANTS OF LOW-DOSE RATE EFFECTS ASSOCIATED WITH RADIOIMMUNOTHERAPY** *ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS*
Knox, S. J., Sutherland, W., Goris, M. L.
1993; 6 (3): 197-207
- **THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW** *CANCER RESEARCH*
Leigh, B. R., Hancock, S. L., Knox, S. J.
1993; 53 (17): 3857-3859
- **CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS** *RADIATION RESEARCH*
Knox, S. J., Sutherland, W., Goris, M. L.
1993; 135 (1): 24-31
- **LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS** *CANCER RESEARCH*
Wilder, R. B., Langmuir, V. K., Mendonca, H. L., Goris, M. L., Knox, S. J.
1993; 53 (13): 3022-3027
- **RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY** *MEDICAL PHYSICS*
Langmuir, V. K., Fowler, J. F., Knox, S. J., Wessels, B. W., SUTHERLAND, R. M., Wong, J. Y.
1993; 20 (2): 601-610
- **Determinants of low dose rate effects associated with radioimmunotherapy.** *Antibody Immunoconjugates and Radiopharmaceuticals*
Knox SJ, Sutherland W, Goris ML
1993; 6: 197-207
- **Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment.** *Radiotherapy Oncology*
Knox SJ, Goris ML, Wessels BW
1993; 25: 219-220
- **THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA** *RADIOTHERAPY AND ONCOLOGY*
Schiele, J., Knox, S. J., RUEHL, W., Goris, M. L.
1992; 24 (3): 169-176
- **OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION** *RADIOTHERAPY AND ONCOLOGY*
Knox, S. J., Goris, M. L., Wessels, B. W.
1992; 23 (2): 111-117
- **THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS** *ANNALS OF THE NEW YORK ACADEMY OF SCIENCES*
Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., Herblin, W. F., Gross, J. L.
1991; 638: 497-502

- **RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY 31ST ANNUAL MEETING OF THE AMERICAN SOC OF THERAPEUTIC RADIOLOGY AND ONCOLOGY**
Corn, B. W., Taylor, B. W., Knox, S. J., Martz, K. L., Flynn, D. F.
PERGAMON-ELSEVIER SCIENCE LTD.1991: 1363-67
- **MYCOSIS-FUNGOIDES ARTHROPATHY ANNALS OF INTERNAL MEDICINE**
Berger, R. G., Knox, S. J., Levy, R., Sklar, J. L., Cohen, P., Reichert, T.
1991; 114 (7): 571-572
- **OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES BLOOD**
Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., Wood, G. S., Hoppe, R., Abel, E. A., Steinman, L., Berger, R. G., Gaiser, C., Young, G., Bindl, et al
1991; 77 (1): 20-30
- **THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS CONF ON THE FIBROBLAST GROWTH FACTOR FAMILY**
Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., Herblin, W. F., Gross, J. L.
NEW YORK ACAD SCIENCES.1991: 497-502
- **DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES CANCER RESEARCH**
Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., RUEHL, W., FINSTON, R., DAYLOLLINI, P., Goris, M. L.
1990; 50 (16): 4935-4940
- **THE CHANGING FACE OF RADIATION ONCOLOGY SOUTHERN MEDICAL JOURNAL**
Meredith, R. F., Halberg, F. E., Knox, S. J.
1990; 83 (4): 488-488
- **HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS CANCER**
Knox, S. J., Kapp, D. S.
1988; 62 (8): 1479-1486
- **2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE JOURNAL OF IMMUNOLOGY**
Shigeta, M., Takahara, S., Knox, S. J., Ishihara, T., Vitetta, E. S., Fathman, C. G.
1986; 136 (1): 34-38
- **EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA THYMUS**
Knox, S. J., ROSENBLATT, L. S., Anderson, R. W., Greenberg, B. R.
1986; 8 (1-2): 33-44
- **RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO HEALTH PHYSICS**
Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., Woerner, S.
1984; 46 (2): 431-433
- **STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS BLOOD**
Knox, S. J., Greenberg, B. R., Anderson, R. W., ROSENBLATT, L. S.
1983; 61 (3): 449-455
- **LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS LEUKEMIA RESEARCH**
Anderson, R. W., Volsky, D. J., Greenberg, B., Knox, S. J., Bechtold, T., Kuszynski, C., Harada, S., Purtilo, D. T.
1983; 7 (3): 389-395
- **RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE INTERNATIONAL JOURNAL OF RADIATION BIOLOGY**
Knox, S. J., Misra, H. P., SHIFRINE, M., ROSENBLATT, L. S.
1982; 41 (3): 283-294
- **Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Stem cells**
Knox, S. J., Wilson, F. D., Miller, C. H., ROSENBLATT, L. S., SHIFRINE, M.

1982; 1 (6): 325-344

- **ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES** *RADIATION RESEARCH*
Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S.
1982; 89 (3): 575-589
- **GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS** *JOURNAL OF CELLULAR BIOCHEMISTRY*
Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M.
1982; 18 (1): 15-24
- **CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA** *BRITISH JOURNAL OF HAEMATOLOGY*
Greenberg, B. R., Wilson, F. D., Woo, L., Knox, S., Jenks, H., Taplett, J.
1981; 48 (1): 85-93
- **INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA** *BLOOD*
Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., Misra, H.
1981; 57 (6): 1043-1048
- **THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM** *EXPERIMENTAL HEMATOLOGY*
Knox, S. J., SHIFRINE, M., Wilson, F. D., ROSENBLATT, L. S.
1981; 9 (9): 926-937
- **A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM** *EXPERIMENTAL HEMATOLOGY*
Wilson, F. D., Dyck, J. A., Knox, S. J., SHIFRINE, M.
1980; 8 (8): 1031-1039
- **Cell-mediated immunity in the dog in relation to disease: A review.** *Comp Immun Microbiol Infect Dis*
Knox SJ, Shifrine M
1980; 2: 405-415
- **Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents.** *Pharmacol Ther*
Hirsh DC, Wiger N, Knox SJ
1979; 2: 275-278
- **PHARMACOKINETICS OF PENICILLIN-G IN TURKEY** *AMERICAN JOURNAL OF VETERINARY RESEARCH*
Hirsh, D. C., Knox, S. J., CONZELMAN, G. M., WIGER, N.
1978; 39 (7): 1219-1221
- **Meeting Report: 29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)**
Hurwitz, A., Lee, S., Knox, S., Holbrook, D., Verdeil, G., Romano, E., Margolin, K., Urga, W., Speiser, D.
2015